Breaking News Instant updates and real-time market news.

AMC

AMC Entertainment

$8.39

0.21 (2.57%)

, CNK

Cinemark

$33.91

(0.00%)

10:55
12/02/19
12/02
10:55
12/02/19
10:55

Benchmark media analyst to hold an analyst/industry conference call

Media Analyst Hickey, along with Patrick Corcoran, VP & Chief Communications Officer and Phil Contrino, Director of Media & Research of the National Association of Theater Owners (NATO) discuss the movie going experience, the slate, streaming, consolidation and other trends of the exhibitor trade industry on an Analyst/Industry conference call to be held on December 2 at 12 pm.

AMC

AMC Entertainment

$8.39

0.21 (2.57%)

CNK

Cinemark

$33.91

(0.00%)

IMAX

Imax

$21.26

-0.22 (-1.02%)

MCS

Marcus

$31.61

0.13 (0.41%)

NCMI

National CineMedia

$6.65

-0.07 (-1.04%)

  • 02

    Dec

  • 16

    Dec

  • 17

    Dec

AMC AMC Entertainment
$8.39

0.21 (2.57%)

11/19/19
MKMP
11/19/19
NO CHANGE
Target $28
MKMP
Buy
Imax growth and margin expansion potential undervalued, says MKM Partners
MKM Partners analyst Eric Handler keeps his Buy rating and $28 price target on Imax (IMAX), saying the company is "executing" on its key initiatives planned for 2019 and is "well set up" heading into 2020 and beyond with declining reliance on North America thanks to its expanding global footprint. The analyst notes however that while Imax is on track to deliver at least a 10% box office growth this year with lengthy international runway and increasing EBITDA margins, the stock is trading at a "modest one-turn premium to traditional exhibitors AMC (AMC) and Cinemark (CNK) despite having a fraction of the capital intensity and twice the margin."
10/22/19
MKMP
10/22/19
NO CHANGE
Target $28
MKMP
Buy
Imax a 'misunderstood, underappreciated' asset, says MKM Partners
MKM Partners analyst Eric Handler is keeping his Buy rating and $28 price target on Imax (IMAX), saying the stock has been "unjustly" punished for the overall 2019 box office weakness and China exposure. The analyst contends however that the company is still on track to grow its own box office sales by 10% this year, while its China box office revenue is up 20% year-to-date. Handler adds that despite these positive trends and a much lower capital intensity relative to traditional theatres, Imax valuation is in-line with AMC Entertainment (AMC) and Cinemark (CNK).
11/22/19
RILY
11/22/19
NO CHANGE
RILY
B. Riley FBR downgrades Cinemark and Marcus, cuts exhibitor targets
B. Riley FBR analyst Eric Wold revisited his exhibitor coverage heading into the "most important stretch" of the Q4 film slate, which will bring Frozen II, Jumanji: The Next Level, and Star Wars: The Rise of Skywalker to screens. However, with the quarter-to-date box office down 14.7%, the analyst now believes Q4 could be relatively flattish year-over-year versus consensus expectations for a mid-single-digit increase. As a result, he lowered his Q4 estimates for the group and believes the full-year 2019 box office could decline around 4.0%. Wold downgraded both Cinemark (CNK) and Marcus (MCS) to Neutral from Buy, saying short-term domestic box office movements are more likely to influence valuation decisions over the next 12-18 months. The analyst also lowered his price target for Buy-rated AMC Entertainment (AMC) to $15 from $19, for Buy-rated Imax (IMAX) to $30 from $34, and for Neutral-rated National CineMedia (NCMI) to $7.50 from $8.50.
11/19/19
RILY
11/19/19
NO CHANGE
RILY
Imax most likely acquisition candidate in exhibition space, says B. Riley FBR
Assistant Attorney General Delrahim commented last night that the Department of Justice's Antitrust Division was moving forward to terminate the Paramount Consent Decrees that have been in place since 1948. In a nutshell, the Paramount Consent Decrees essentially ended an era when major movie studios not only controlled film making and had locks on the stars/talent, but also owned the movie theaters themselves, B. Riley FBR analyst Eric Wold tells investors in a research note. The analyst points out that AMC Entertainment (AMC), Imax (IMAX) and Cinemark Holdings (CNK) traded higher in after-hours last night. Although Wold does not anticipate that acquiring a theater circuit would be on the top of the strategy road maps for the major film studios, he believes Imax is the most likely acquisition candidate, regardless of the expected termination of the Paramount Consent Decrees. Given the company's agnostic position with the various major studios and exhibition chains, the most likely buyer would be private equity, as opposed to any studio or theater chain, the analyst contends.
CNK Cinemark
$33.91

(0.00%)

11/22/19
RILY
11/22/19
DOWNGRADE
Target $37
RILY
Neutral
Cinemark downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Eric Wold downgraded Cinemark to Neutral from Buy with a price target of $37, down from $46.50. Consecutive annual box office declines could pressure valuations of the theater companies into mid-2020, Wold tells investors in a research note.
11/22/19
11/22/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cognizant (CTSH) downgraded to Underperform from Hold at Needham with analyst Mayank Tandon saying his "deeper dive" analysis into the near-term challenges facing the company suggests that consensus expectations are "too high," with potential downward revisions coming over the next several months. 2. TechnipFMC (FTI) downgraded to Hold from Buy at Berenberg with analyst Henry Tarr saying he views the company's Q3 results as disappointing and believes its margin weakness will persist into 2020. 3. Enanta (ENTA) downgraded to Market Perform from Outperform at JMP Securities with analyst Liisa Bayko saying that while the company's fiscal Q4 results contained no surprises, she's more cautious on the competitive profile for FXR agonist EDP-305. 4. Marcus (MCS) and Cinemark (CNK) downgraded to Neutral from Buy at B. Riley FBR. 5. Universal Display (OLED) downgraded to Market Perform from Outperform at Cowen with analyst Krish Sankar saying it is a pure play name in the OLED growth theme but it trades at a premium valuation and appears to be fairly valued. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IMAX Imax
$21.26

-0.22 (-1.02%)

11/01/19
BRRR
11/01/19
NO CHANGE
Target $27
BRRR
Outperform
Imax China success highlighted by record sales during holiday, says Barrington
Barrington analyst James Goss keeps his Outperform rating and $27 price target on Imax, saying the company has been "significantly outperforming trends" in many of its key markets. The analyst points to Imax's record box office in China during its National Day holiday, highlighting its ability to showcase multiple titles and "program its footprint" based on "audience reception" as a key driver of its success. Goss further cites the company's increasing penetration of "laser" projection technology as a new differentiating quality factor for Imax.
MCS Marcus
$31.61

0.13 (0.41%)

04/26/19
RILY
04/26/19
UPGRADE
Target $46
RILY
Buy
Marcus upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Eric Wold upgraded Marcus Corporation to Buy from Neutral and raised his price target for the shares to $46 from $41. The analyst sees an "attractive setup" for valuation upside into the summer box office following the company's better than expected Q1 results.
11/22/19
RILY
11/22/19
DOWNGRADE
Target $37
RILY
Neutral
Marcus downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Eric Wold downgraded Marcus to Neutral from Buy with a price target of $37, down from $46. Consecutive annual box office declines could pressure valuations of the theaters companies into mid-2020, Wold tells investors in a research note.
NCMI National CineMedia
$6.65

-0.07 (-1.04%)

06/19/19
06/19/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lamb Weston (LW) upgraded to Buy from Neutral at Goldman Sachs with analyst Adam Samuelson saying the shares offer an "attractive valuation risk/reward," after declining 18.6% year-to-date. 2. TripAdvisor (TRIP) upgraded to Buy from Hold at SunTrust with analyst Naved Khan noting that the market valuation is placing more emphasis on the company's EBITDA multiple of the slower-growing Core business, even though its Experiences segment has generated annual growth of over 30% and now represents nearly a third of total sales. 3. Six Flags (SIX) upgraded to Outperform from Neutral at Wedbush with analyst James Hardiman stating believes that a number of potential catalysts line up nicely for the company, most notably Per-Capita spending improvements driven by the Membership 2.0 program, positive news flow from the company's international business and easy weather comparisons. 4. National CineMedia (NCMI) upgraded to Outperform from Neutral at Wedbush with analyst Michael Pachter saying he is less concerned about reserved seating driving later arrivals as the company has shown that it can recoup ad dollars elsewhere. 5. U.S. Steel (X) upgraded to Buy from Sell at Vertical Group with analyst Gordon Johnson after the company did the "unthinkable" and idled two U.S. plants and one in the EU. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/05/19
RILY
11/05/19
DOWNGRADE
Target $8.5
RILY
Neutral
National CineMedia downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Eric Wold downgraded National CineMedia to Neutral from Buy with a price target of $8.50, down from $9.75.
11/07/19
BRRR
11/07/19
UPGRADE
Target $9.5
BRRR
Outperform
National CineMedia upgraded to Outperform from Market Perform at Barrington
Barrington analyst James Goss upgraded National CineMedia to Outperform from Market Perform with a $9.50 price target. The post-earnings selloff in the shares has created an opportunity with the stock now yielding 9.5%, Goss tells investors in a research note. National CineMedia's "stable" business model creates a situation in which the company can pay out roughly 80% of its free cash flow in dividends and distributions, the analyst points out.

TODAY'S FREE FLY STORIES

ATRC

AtriCure

$30.99

1.29 (4.34%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
AtriCure management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAD

Acadia

$51.37

0.915 (1.81%)

, AMGN

Amgen

$233.74

0.3 (0.13%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Clinical Trials on Alzheimer's Disease to hold conference »

12th Clinical Trials on…

ACAD

Acadia

$51.37

0.915 (1.81%)

AMGN

Amgen

$233.74

0.3 (0.13%)

AZN

AstraZeneca

$47.68

0.06 (0.13%)

BIIB

Biogen

$300.27

0.98 (0.33%)

CLB

Core Laboratories

$46.19

1.94 (4.38%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

MRK

Merck

$88.84

0.09 (0.10%)

NVS

Novartis

$92.08

0.42 (0.46%)

RHHBY

Roche

$0.00

(0.00%)

TAK

Takeda Pharmaceutical

$20.27

-0.16 (-0.78%)

VCNX

Vaccinex

$4.95

-0.05 (-1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 16

    Dec

  • 17

    Dec

  • 21

    Jan

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 05

    Feb

  • 14

    Mar

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

FITB

Fifth Third

$30.24

0.365 (1.22%)

, CSCO

Cisco

$43.83

0.29 (0.67%)

18:37
12/06/19
12/06
18:37
12/06/19
18:37
Hot Stocks
Fifth Third issues statement on temporary network outage »

Fifth Third Bank (FITB)…

FITB

Fifth Third

$30.24

0.365 (1.22%)

CSCO

Cisco

$43.83

0.29 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 08

    Jan

  • 12

    Feb

STML

Stemline

$10.33

0.5 (5.09%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

18:33
12/06/19
12/06
18:33
12/06/19
18:33
Hot Stocks
Stemline names Robert Francomano as Chief Commercial Officer »

Most recently, Francomano…

STML

Stemline

$10.33

0.5 (5.09%)

PFE

Pfizer

$38.29

0.26 (0.68%)

GSK

GlaxoSmithKline

$45.51

0.29 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

GOL

Gol Linhas

$17.39

1.07 (6.56%)

18:31
12/06/19
12/06
18:31
12/06/19
18:31
Hot Stocks
Gol Linhas announces preliminary traffic figures for November »

GOL's domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVB

Navidea

$0.97

0.07 (7.78%)

18:25
12/06/19
12/06
18:25
12/06/19
18:25
Syndicate
Navidea announces $1.9M private placement »

Navidea announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFC

Ellington Financial

$18.22

0.09 (0.50%)

18:23
12/06/19
12/06
18:23
12/06/19
18:23
Hot Stocks
Ellington Financial reports estimated book value per share $18.51 on November 30 »

This estimate includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOOT

Boot Barn

$41.93

0.81 (1.97%)

18:22
12/06/19
12/06
18:22
12/06/19
18:22
Hot Stocks
Boot Barn CEO: More than 80% of our business is in the store »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$9.24

0.1 (1.09%)

18:18
12/06/19
12/06
18:18
12/06/19
18:18
Hot Stocks
Ericsson to pay over $1B to settle FCPA case »

Ericsson has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GLD

SPDR Gold Shares

$137.59

-1.42 (-1.02%)

17:55
12/06/19
12/06
17:55
12/06/19
17:55
Hot Stocks
SPDR Gold Shares holdings fall to 886.23MT from 888.57MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PICO

PICO Holdings

$10.81

0.31 (2.95%)

17:45
12/06/19
12/06
17:45
12/06/19
17:45
Hot Stocks
PICO Holdings sells long-term storage credits for $8.7M in Arizona »

PICO Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QHC

Quorum Health

$0.95

0.0522 (5.81%)

17:31
12/06/19
12/06
17:31
12/06/19
17:31
Hot Stocks
Quorum Health receives NYSE continued listing standard notice »

Quorum Health Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:30
12/06/19
12/06
17:30
12/06/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Support.com »

Support.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXRX

Baudax Bio

$6.69

0.34 (5.35%)

17:29
12/06/19
12/06
17:29
12/06/19
17:29
Syndicate
Breaking Syndicate news story on Baudax Bio »

Baudax Bio files $125M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

LMT

Lockheed Martin

$387.10

1.175 (0.30%)

17:25
12/06/19
12/06
17:25
12/06/19
17:25
Hot Stocks
Lockheed Martin awarded $153.39M Navy contract modification »

Lockheed Martin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENV

Envestnet

$71.72

1.27 (1.80%)

17:23
12/06/19
12/06
17:23
12/06/19
17:23
Syndicate
Breaking Syndicate news story on Envestnet »

Envestnet files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$344.79

0.4 (0.12%)

17:20
12/06/19
12/06
17:20
12/06/19
17:20
Hot Stocks
Northrop Grumman awarded $189M Navy contract modification »

Northrop Grumman was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:03
12/06/19
12/06
17:03
12/06/19
17:03
Hot Stocks
Support.com announces special distribution of $1.00 per share »

The record date for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:01
12/06/19
12/06
17:01
12/06/19
17:01
Hot Stocks
Breaking Hot Stocks news story on Support.com »

Support.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RZLT

Rezolute

$0.00

(0.00%)

17:00
12/06/19
12/06
17:00
12/06/19
17:00
Syndicate
Breaking Syndicate news story on Rezolute »

Rezolute files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

16:58
12/06/19
12/06
16:58
12/06/19
16:58
Periodicals
U.S. mulls putting Amazon foreign sites on 'Notorious Markets' list, WSJ says »

The Trump administration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

16:55
12/06/19
12/06
16:55
12/06/19
16:55
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.